By Ian Walker

GlaxoSmithKline PLC (GSK.LN) said Tuesday that the U.S. Food and Drug Administration has approved Trelegy Ellipta for patients with chronic obstructive pulmonary disease.

Trelegy Ellipta hasn't been indicated for relief of acute bronchospasm or the treatment of asthma, Glaxo said.

It added that, following the approval, Trelegy Ellipta will be available in the U.S. shortly.

Regulatory applications have been submitted, and are undergoing assessment in a number of other regions, including the European Union, Australia and Canada.

Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

(END) Dow Jones Newswires

September 19, 2017 02:37 ET (06:37 GMT)

Copyright (c) 2017 Dow Jones & Company, Inc.
GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.